title: Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation.
abstract: Serologic evidence of resolved hepatitis B virus (HBV) infection has been associated with reactivation of hepatitis after allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the true impact of this finding is unknown. We conducted a retrospective matched-control analysis of the outcomes of 76 patients with positive HBV core antibody (HBcAb) and negative HBV surface antigen (HBsAg) at the time of allo-HSCT for hematologic or solid malignancies. Control patients (matched controls), with negative serology for HBV and other viral hepatitides, were matched by age, diagnosis, disease risk, intensity of conditioning regimen, and donor type. In addition, the HBcAb-positive patients and all seronegative patients (all controls, n = 1858) undergoing transplantation during the same period were compared to adjust for other confounding effects. Patient characteristics and baseline hepatic function studies were similar in the HBcAb-positive and matched control groups. The cumulative incidence of hepatitis B reactivation (defined as the emergence of HBsAg in serum) was 11.6% at 3 years. There were no significant differences in overall survival, relapse, nonrelapse mortality, and incidence of acute graft-versus-host disease between the HBcAb-positive and control groups. Our data suggest that seropositivity for HBcAb and seronegativity for HBsAg at the time of transplantation does not seem to adversely affect outcome after allo-HSCT.
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Ramos
authors.forename: Rima M
authors.initials: RM
authors.lastname: Saliba
authors.forename: Leandro
authors.initials: L
authors.lastname: de Pádua Silva
authors.forename: Ola
authors.initials: O
authors.lastname: Khorshid
authors.forename: Elizabeth J
authors.initials: EJ
authors.lastname: Shpall
authors.forename: Sergio
authors.initials: S
authors.lastname: Giralt
authors.forename: Poliana A
authors.initials: PA
authors.lastname: Patah
authors.forename: Chitra M
authors.initials: CM
authors.lastname: Hosing
authors.forename: Uday R
authors.initials: UR
authors.lastname: Popat
authors.forename: Gabriela
authors.initials: G
authors.lastname: Rondon
authors.forename: Yago
authors.initials: Y
authors.lastname: Nieto
authors.forename: Richard E
authors.initials: RE
authors.lastname: Champlin
authors.forename: Marcos
authors.initials: M
authors.lastname: de Lima
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D019337:Hematologic Neoplasms / Q000150:complications / Q000401:mortality / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000401:mortality; D006509:Hepatitis B; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D015996:Survival Rate; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014775:Virus Activation; D055815:Young Adult